Table 1. Inhibition of cholesterol and isoprenoids results in dose dependent craniofacial abnormalities.
| Treatment | Total Embryos | Percent Survival (%) | Craniofacial abnormalities | p-value |
|---|---|---|---|---|
| DMSO | 90 | 100 | 1 | |
| Atorvastatin-2.5uM | 30 | 100 | 23 | <0.0001 |
| Lonafarnib-8uM | 40 | 95 | 35 | <0.0001 |
| Ro 48 8071–1.0uM | 18 | 92 | 1 | 0.3069 |
| Ro 48 8071–2.0uM | 42 | 100 | 5 | 0.0125 |
| Ro 48 8071–3.0uM | 15 | 100 | 14 | <0.0001 |
| Ro 48 8071–4.0uM | 25 | 0 | N/A | N/A |
Abnormal Phenotype includes truncated Meckel’s cartilage, presence or absence of an inverted ceratohyal, and the loss of the posterior ceratobranchial cartilages. Statistical analysis was performed with a Fisher’s Exact T-test.